Company Description
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024.
Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2015 |
| IPO Date | May 24, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 366 |
| CEO | Sanj Patel |
Contact Details
Address: 105 Piccadilly, 2nd Floor London, W1J 7NJ United Kingdom | |
| Phone | 44 78 1431 9100 |
| Website | kiniksa.com |
Stock Details
| Ticker Symbol | KNSA |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001730430 |
| CUSIP Number | G5269C101 |
| ISIN Number | GB00BRXB0C07 |
| Employer ID | 98-1795578 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanj K. Patel | Chief Executive Officer and Chairman of the Board |
| Mark A. Ragosa C.F.A. | Senior Vice President and Chief Financial Officer |
| Ross Michael Moat | Chief Operating Officer and Principal Operating Officer |
| Dr. John F. Paolini FACC, M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Eben Tessari | Chief Strategy Officer |
| Michael R. Megna CPA | Senior Vice President and Chief Accounting Officer |
| Mei Jang | Senior Vice President and Chief Technical Officer |
| Jonathan Kirshenbaum | Investor Relations Officer |
| Douglas Barry | Senior Vice President, Chief Legal Officer and Secretary |
| Megan Woods M.B.A. | Senior Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2026 | SCHEDULE 13G | Filing |
| Mar 2, 2026 | 144 | Filing |
| Feb 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Jan 14, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 15, 2025 | 144 | Filing |
| Dec 8, 2025 | 144 | Filing |